# R21/MM Dosing, Presentations, and Preservatives

> **NCT07194668** · PHASE4 · NOT_YET_RECRUITING · sponsor: **University of Oxford** · enrollment: 375 (estimated)

## Conditions studied

- Plasmodium Falciparum Malaria
- Malaria
- Vaccine Reaction

## Interventions

- **BIOLOGICAL:** 10μg R21/50μg Matrix-M
- **BIOLOGICAL:** 5μg R21/50μg Matrix-M with adaptor preservative free
- **BIOLOGICAL:** 5μg R21/50μg Matrix-M with 2PE preservative

## Key facts

- **NCT ID:** NCT07194668
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 375 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07194668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07194668, "R21/MM Dosing, Presentations, and Preservatives". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07194668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*